A multisite implementation of a real-time polymerase chain reaction assay to predict ciprofloxacin susceptibility in Neisseria gonorrhoeae.
Adolescent
Adult
Aged
Anti-Bacterial Agents
/ pharmacology
Ciprofloxacin
/ pharmacology
DNA Gyrase
/ genetics
Drug Resistance, Bacterial
Genotype
Genotyping Techniques
/ methods
Gonorrhea
/ microbiology
Humans
Los Angeles
Microbial Sensitivity Tests
/ methods
Middle Aged
Neisseria gonorrhoeae
/ drug effects
Philadelphia
Real-Time Polymerase Chain Reaction
/ methods
San Francisco
Time Factors
Young Adult
Antibiotic resistance
Antimicrobial stewardship
Gonorrhea
Molecular surveillance
Journal
Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
08
06
2018
revised:
26
12
2018
accepted:
27
12
2018
pubmed:
7
2
2019
medline:
8
11
2019
entrez:
7
2
2019
Statut:
ppublish
Résumé
There are no commercially available Food and Drug Administration-cleared rapid tests for Neisseria gonorrhoeae antimicrobial susceptibility testing. This study evaluated the performance of a laboratory-developed real-time polymerase chain reaction assay for genotyping the gyrA gene to determine antimicrobial susceptibility to ciprofloxacin. Validation and clinical performance of the gyrA assay were evaluated across 3 geographic locations (Los Angeles, San Francisco, Philadelphia). Following validation, clinical specimens were collected in Aptima Combo2® CT/NG transport medium from asymptomatic persons who tested positive for Neisseria gonorrhoeae and evaluated for assay percent reportable (i.e., proportion of N. gonorrhoeae-positive specimens that yielded a gyrA genotype). The percentage of gyrA genotyping results differed by laboratory and specimen type. The proportion of specimens that were reportable was best for urine/genital specimens (genotyped = 76.4% (95% confidence interval, 69.9-82%)) followed by rectal (genotyped = 67.2% (95% confidence interval, 63.4-70.6%)) and then pharyngeal specimens (genotyped = 36.1%, (95% confidence interval, 31.9-40.5%)). Overall, asymptomatic patients with N. gonorrhoeae yielded an interpretable genotype 57.2% (784/1370) of the time, of which 480 were wild-type gyrA, resulting in 61% (480/784) being potentially treatable with ciprofloxacin.
Identifiants
pubmed: 30723007
pii: S0732-8893(19)30028-8
doi: 10.1016/j.diagmicrobio.2018.12.018
pmc: PMC7427424
mid: NIHMS1615794
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ciprofloxacin
5E8K9I0O4U
DNA Gyrase
EC 5.99.1.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
213-217Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201300014I
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI139265
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI117256
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Curr Opin Infect Dis. 2016 Feb;29(1):45-51
pubmed: 26658656
MMWR Surveill Summ. 2016 Jul 15;65(7):1-19
pubmed: 27414503
Clin Infect Dis. 2017 May 1;64(9):1268-1270
pubmed: 28034887
MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137
pubmed: 26042815
Genitourin Med. 1996 Aug;72(4):295-7
pubmed: 8976839
Sex Transm Infect. 2009 Jun;85(3):159-60
pubmed: 19478103
PLoS Med. 2017 Jul 7;14(7):e1002344
pubmed: 28686231
J Antimicrob Chemother. 2015 Feb;70(2):374-81
pubmed: 25331059
J Antimicrob Chemother. 2016 Feb;71(2):353-6
pubmed: 26538505
J Clin Microbiol. 2016 Mar;54(3):805-8
pubmed: 26739156
J Clin Microbiol. 2007 Apr;45(4):1250-4
pubmed: 17267635
MMWR Morb Mortal Wkly Rep. 2007 Apr 13;56(14):332-6
pubmed: 17431378
Sex Transm Infect. 2002 Aug;78(4):232-4
pubmed: 12181457
N Engl J Med. 2016 Jun 23;374(25):2504-6
pubmed: 27332921
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28848021
PLoS One. 2015 Dec 08;10(12):e0143304
pubmed: 26646541
Sex Transm Dis. 2018 Feb;45(2):87-91
pubmed: 29329176